{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:55:26Z","timestamp":1790470526381,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T00:00:00Z","timestamp":1532736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,5]]},"DOI":"10.1093\/cid\/ciy600","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T03:41:13Z","timestamp":1532662873000},"page":"1058-1062","source":"Crossref","is-referenced-by-count":53,"title":["Delafloxacin: A New Anti\u2013methicillin-resistant <i>Staphylococcus aureus<\/i> Fluoroquinolone"],"prefix":"10.1093","volume":"68","author":[{"given":"Louis D","family":"Saravolatz","sequence":"first","affiliation":[{"name":"St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E","family":"Stein","sequence":"additional","affiliation":[{"name":"Michigan State University School of Medicine, East Lansing"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,28]]},"reference":[{"key":"key\n\t\t\t\t2019030423562373700_CIT0001","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0002","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0003","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0004","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0005","first-page":"e02803","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0006","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance","volume":"60","author":"Soge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/dkh304","article-title":"The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae","volume":"54","author":"Hammerschlag","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0008","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1128\/AAC.47.12.3973-3975.2003","article-title":"Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0009","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0010","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcph.1041","article-title":"Delafloxacin pharmacokinetics in subjects with varying degrees of renal function","volume":"58","author":"Hoover","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0013","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.clinthera.2017.04.009","article-title":"The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin","volume":"39","author":"Paulson","year":"2017","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0014","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcph.817","article-title":"Clinical pharmacology of delafloxacin in patients with hepatic impairment","volume":"57","author":"Hoover","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens","volume":"48","author":"Thabit","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0016","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1128\/AAC.00647-16","article-title":"In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model","volume":"60","author":"Lepak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0017","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/46.5.669","article-title":"Application of fluoroquinolone pharmacodynamics","volume":"46","author":"Wright","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0018","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0019","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0020","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0021","doi-asserted-by":"crossref","first-page":"e00772","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0022","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0023","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.juro.2015.01.094","article-title":"Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae","volume":"194","author":"So","year":"2015","journal-title":"J Urol"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0024","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijantimicag.2012.02.011","article-title":"Transferable mechanisms of quinolone resistance","volume":"40","author":"Ruiz","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019030423562373700_CIT0025","first-page":"49","article-title":"Delafloxacin (Baxdela)\u2013A new fluoroquinolone antibiotic","volume":"60","year":"2018","journal-title":"Med Lett Drugs Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/6\/1058\/28009531\/ciy600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T04:56:42Z","timestamp":1551761802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/6\/1058\/5061005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,28]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,7,28]]},"published-print":{"date-parts":[[2019,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy600","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,15]]},"published":{"date-parts":[[2018,7,28]]}}}